Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2018

View Archived Issues

Exosomes deliver no-NO arginase in diabetes

Novel TZD CMHX-008 maintains insulin sensitization with minor effects on weight gain and bone loss

Feeding findings may hold key to appetite control

Achillion initiates first-in-human study of ACH-5548

Researchers develop a rat model of diabetic cardiomyopathy for cardiovascular evaluation

FDA clears IND for Adagene's phase I study of ADG-106

Investigating isoflavonoids for the potential treatment of obesity and diabetes

[225Ac]DOTA-PEG7-5B1 as pretargeted radioimmunotherapy for pancreatic ductal adenocarcinoma

BioSight receives clearance to initiate phase IIb study of BST-236 in AML

Ovid Therapeutics initiates phase II ROCKET trial of OV-101 in fragile X syndrome

Tegsedi approved in the E.U. for the treatment of hATTR

First patient dosed in phase II study of CV-301 plus nivolumab in metastatic colorectal cancer

Recursion set to begin phase I study of AI/ML-based drug candidate, REC-994

Advaxis withdraws conditional MAA for axalimogene filolisbac, advances ADXS-HOT program

Argenx presents phase II data for ARGX-113 in myasthenia gravis

OG-716, a lantibiotic that is active against Clostridium difficile infections

Amgen describes new beta-secretase inhibitors

National Center for Global Health and Medicine, Kumamoto University and Yamasa patent antivirals

Galapagos, AbbVie discover CFTR modulators

Pivotal study of KP-415 in children with ADHD meets primary efficacy endpoint

New phase II trial explores voclosporin ophthalmic solution for dry eye syndrome

Genmab and Immatics partner on next-generation bispecific cancer immunotherapies

New phase III trial investigates etripamil for termination of spontaneous PSVT

TAS-114 combined with S-1 shows preliminary efficacy in pretreated advanced gastric cancer patients

Japanese researchers present phase II data on TAS-205 in patients with DMD

Phase III maintenance trial of Ninlaro in multiple myeloma meets primary endpoint

Phase III study of Imbruvica in treatment-naive DLBCL misses primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...